All Stories

  1. Design, simulate, refine: simulation-guided clinical trials for accelerated drug development
  2. Pre‐Posterior Distributions in Drug Development and Their Properties
  3. Performance Evaluation of Interim Analysis in Bioequivalence Studies
  4. Absolute Power Corrupts Absolutely: A Review of the Use of Unconditional Probabilities in the Planning of Clinical Trials
  5. Probability of success and group sequential designs
  6. On implementing J effreys' substitution likelihood for B ayesian inference concerning the medians of unknown distributions
  7. Hybrid Frequentist/Bayesian Power and Bayesian Power in Planning Clinical Trials
  8. Optimising the trade‐off between type I and II error rates in the Bayesian context
  9. How to design a dose-finding study using the continual reassessment method
  10. Minimizing Patient Burden Through the Use of Historical Subject-Level Data in Innovative Confirmatory Clinical Trials
  11. Justify your alpha
  12. Statistical issues in first-in-human studies on BIA 10-2474: Neglected comparison of protocol against practice
  13. Response-adaptive clinical trials: case studies in the medical literature
  14. Simulation-based sample-sizing and power calculations in logistic regression with partial prior information
  15. The predictive distribution of the residual variability in the linear-fixed effects model for clinical cross-over trials
  16. Idle thoughts of a ‘well-calibrated’ Bayesian in clinical drug development
  17. How to test hypotheses if you must
  18. Limitations of within-person study designs
  19. Medical Statistics
  20. Fracture risk with use of liver enzyme inducing antiepileptic drugs in people with active epilepsy: Cohort study using the General Practice Research Database
  21. Advancing clinical trial design in pulmonary hypertension
  22. A dual-centre, cohort comparison of open, laparoscopic and robotic-assisted radical cystectomy
  23. Within-person study designs had lower precision and greater susceptibility to bias because of trends in exposure than cohort and nested case–control designs
  24. Source Data Verification by Statistical Sampling: Issues in Implementation
  25. Cutaneous lymphocyte antigen and α4β7 T-lymphocyte responses are associated with peanut allergy and tolerance in children
  26. Discussions
  27. Estimates of Outcomes Up to Ten Years after Stroke: Analysis from the Prospective South London Stroke Register
  28. Short Term Response To Sildenafil Therapy For Pulmonary Arterial Hypertension Is Associated With Long Term Outcome
  29. Parental assessment of adolescent quality of life: can it replace self-assessment?
  30. Risk and Cumulative Risk of Stroke Recurrence: A Systematic Review and Meta-Analysis
  31. Cluster randomised trial in the General Practice Research Database: 1. Electronic decision support to reduce antibiotic prescribing in primary care (eCRT study)
  32. Potential application of item-response theory to interpretation of medical codes in electronic patient records
  33. Cluster Randomized Controlled Trial of a Patient and General Practitioner Intervention to Improve the Management of Multiple Risk Factors After Stroke: Stop Stroke
  34. Entwicklung der deutschen Version der Patientenzufriedenheits-Skala (SASC) für den Einsatz bei Patienten nach Schlaganfall
  35. Frequency and predictors for the risk of stroke recurrence up to 10 years after stroke: the South London Stroke Register
  36. Nurse delivered endoscopy
  37. Black and minority ethnic men who have sex with men: a London genitourinary medicine clinic experience
  38. Ethnic Group Disparities in 10-Year Trends in Stroke Incidence and Vascular Risk Factors: The South London Stroke Register (SLSR)
  39. European regulatory agencies should employ full time statisticians
  40. Flexible Design and Efficient Implementation of Adaptive Dose-Finding Studies
  41. Discussion of the “White Paper of the PhRMA Working Group on Adaptive Dose-Ranging Designs”
  42. Adaptive Designs in Clinical Drug Development: Opportunities, Challenges, and Scope Reflections Following PhRMA's November 2006 Workshop
  43. Simulation-based sequential Bayesian design
  44. Statistical issues in first-in-man studies
  45. 25 years of Bayesian methods in the pharmaceutical industry: a personal, statistical bummel
  46. The association of post-stroke neurological improvement with risk of subsequent deterioration due to stroke events
  47. A Bayesian Decision-Theoretic Dose-Finding Trial
  48. Guest Editors' Note for the Special Issue on “Design and Analysis of Dose-Response Clinical Trials”
  49. Implementation of a Bayesian adaptive design in a proof of concept study
  50. The professionalization of the 'shoe clerk'
  51. ASTIN: a Bayesian adaptive dose–response trial in acute stroke
  52. Career story: Pharmaceutical Statistician
  53. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): An Adaptive Dose-Response Study of UK-279,276 in Acute Ischemic Stroke
  54. The number needed to treat: a useful clinical measure or a case of the Emperor's new clothes?
  55. Do statisticians count? A personal view
  56. Adaptive Bayesian Designs for Dose-Ranging Drug Trials
  57. A Comment on Optimal Allocations for Bioequivalence Studies
  58. Issues for statisticians in pharmaco-economic evaluations
  59. Issues for statisticians in pharmaco‐economic evaluations
  60. Bayesian and frequentist approaches to the cross-over trial
  61. Joint equivalence of means and variances of two populations
  62. A Comment on Interim Analyses in Crossover Trials
  63. Extending a Bayesian Analysis of the Two-Period Crossover to Accommodate Missing Data
  64. Extending a Bayesian analysis of the two-period crossover to accommodate missing data
  65. A Further Note on Sampling to Locate Rare Defectives with Strong Prior Evidence
  66. Bayesian analyses of two-treatment crossover studies
  67. Crossover studies
  68. Extending a Bayesian analysis of the two-period crossover to allow for baseline measurements
  69. Statistical Methods in Analytical Chemistry.
  70. A further note on sampling to locate rare defectives with strong prior evidence
  71. Cross-Over Trials in Clinical Research.
  72. Measuring Your Posterior Beliefs That you can Count Properly
  73. Design and analysis of bioavailability and bioequivalence studies. Shein-Chung Chow and Jen-Pei Liu, Marcel Dekker, New York, 1992. No. of pages: x + 416. Price: $125. ISBN 0-8247-8682-3
  74. Confidence Intervals on Variance Components.
  75. `Student'-A Statistical Biography of William Sealy Gosset: Based on the Writings of E. S. Pearson.
  76. Confidence Intervals and Sample Sizes
  77. On the construction of shortest confidence intervals and Bayesian highest posterior density intervals
  78. Predictive Probability in Clinical Trials
  79. A further note on some wishart expectations
  80. A Quasirandom Approach to Integration in Bayesian Statistics
  81. A Two-Stage Procedure for Bioequivalence Studies
  82. Discussion of Piegorsch and Gladen (1986)
  83. A Note on the Analysis of the Two-Period Crossover Design When the Period-Treatment Interaction is Significant
  84. Applications of Bayesian Software: Two Examples
  85. Bayesian Methods in Practice: Experiences in the Pharmaceutical Industry
  86. The role of Schmidt-Lanterman incisures in Wallerian degeneration
  87. A Bayesian Analysis of the Two-Period Crossover Design for Clinical Trials
  88. A non-parametric confidence interval method
  89. Seasonal variation of temperatures in rabbits
  90. Tests of sphericity of normal distributions and the analysis of repeated measures designs
  91. Fully automated and fast image analysis of autoradiographs with a TAS-Leitz. Determination of size, Feulgen fluorescence and grain counts of individual nuclei and their evaluation by a simplified cluster analysis
  92. Bayesian Approach to Bioequivalence Assessment: An Example
  93. Pharmacokinetic and pharmacodynamic studies of single oral doses of metoprolol in normal volunteers
  94. Medical Statistics
  95. Medical Statistics